Karyopharm Therapeutics logo
Karyopharm Therapeutics
KPTI | NASDAQ
Chart Builder DCF Calculator
$0.11
-$0.55 (-83.38%)
At close: Nov 2, 2026, 4:00 PM ET

Karyopharm Therapeutics Company Profile

Company profile explained

Company Profile

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Key Executives

Name Position
Richard A. Paulson President, Chief Executive Officer & Director
Lori A. Macomber Executive Vice President, Chief Financial Officer & Treasurer
Michael J. Mano Executive VP, Chief Legal Officer & Secretary
Brendan Twohig Strong Senior Vice President of Investor Relations
James Accumanno Chief Compliance Officer
Kristin Abate Vice President, Chief Accounting Officer & Assistant Treasurer
Lisa DiPaolo Executive Vice President & Chief Human Resource Officer
Reshma Rangwala Executive Vice President, Chief Medical Officer & Head of Research
Sharon Shacham Co-Founder & Chairman of Scientific Advisory Board
Stuart Poulton Executive Vice President & Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 22, 2026 8-K Current Report
Oct 19, 2026 4 Filing
Oct 14, 2026 8-K Current Report
Oct 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 02, 2026 4 Filing
Sep 25, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 25, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 18, 2026 8-K Current Report
Sep 11, 2026 8-K Current Report
View All SEC Filings ➞
Karyopharm Therapeutics
Karyopharm Therapeutics logo
Country United States
IPO Date Nov 6, 2013
Industry Biotechnology
Sector Healthcare
Employees 228
CEO Richard A. Paulson

Contact Details

85 Wells Avenue Newton, Massachusetts 02459-3298 United States

Stock Details

Ticker Symbol KPTI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001503802
CUSIP Number 48576U205
ISIN Number US48576U2050
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.